Pivotal's scientific team is composed of respected researchers with numerous other drugs in clinical trials throughout the world. Our business team includes experienced professionals who have managed drug development through clinical trials to FDA approval. The Advisory Board consist of distinguished scientists and scientist/businessmen who are actively assisting Pivotal Biosciences.

Business Team

Dimitri Villard, M.S.
Chairman of the Board, President

Executive Committee, Tech Coast Angels; former Director of investment banking firm SG Cowen; former Chairman/CEO, ArtistDirect

Tom Silberg
Director

CEO, Stem Protein; former President of Abraxis Pharmaceutical Products, former COO of Tercica and Ligan Pharmaceuticals, 27 years at Hoffman-LaRoche.

Stephen Flaim, Ph.D.
Director

Tech Coast Angels, Board of Governors; former Sr. VP, Gallileo Labs, Rega BioSciences; VP, Alliance Pharmaceuticals; Division Director, Bristol-Meyers Squibb

Paul Cossum, Ph.D.
Director

Exec VP, ESSA Pharmaceuticals, former CEO Texas BioAlliance, Pro Acta; former EVP New Biotics, ISIS Pharmaceuticals

Science Team

Alan L. Epstein, M.D., Ph.D.
Professor, Dept. of Pathology, University of Southern California Keck School of Medicine

Developed a novel method to target necrotic cells in human cancers, published over 120 articles on cancer research, numerous awards

 

Pivotal's Scientific and Business Advisory Board consists of highly respected individuals in their scientific fields who provide an invaluable resource to Pivotal through the R&D process. Their collective experience includes domain expertise in the development and testing of new therapies for cancer, immunotherapy and vaccine development, infectious diseases, pharmacology, biophysics and structural biology at the USC Keck School of Medicine, M.D. Anderson Cancer Center/University of Texas, and The Mayo Clinic.

Scientific and Business Advisory Board

Robert Figlin, M.D., Chairman
Deputy Director, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai; former Chair, Division of Oncology & Therapeutics City of Hope

Dr. Figlin is a former Professor at UCLA and a co-founder of Agensys.

Peter Anderson, M.D., Ph.D.
Associate Professor of Hematology/Oncology, Mayo Medical School

An expert on the development and testing of new therapies for cancer, especially in new formulations of IL-2 and methods to improve its half-life and delivery into patients.

Elizabeth Grimm, Ph.D.
Professor of Cancer Biology, University of Texas, M.D. Anderson Cancer Center

A noted investigator of T-cell immunity who has devoted a large part of her career to the study and use of IL-2 for the treatment of cancer.

Steven Richieri, M.B.A.
Senior VP, Banyan Biomarkers

20 year executive veteran in biotech R&D, with successful commercialization experience of biopharmaceuticals at PhotoThera, Egea BioSciences, Immune Response and other biotechnology companies.

[ HOME ]

[PRODUCT PIPELINE]

[ IN THE NEWS ]

Pivotal BioSciences, Inc.
8721 Santa Monica Blvd.
Suite 100
Los Angeles, CA 90069

Tel: (310) 734-4551

Email: info@pivotalbiosciences.com



Pivotal BioSciences, Inc. 2016. All Rights Reserved.